Permutation Tests for Phase III Clinical Trials

Vance Berger and Anastasia Ivanova
Additional contact information
Vance Berger: U.S. Food and Drug Administration
Anastasia Ivanova: University of North Carolina

Chapter 14 in Applied Statistics in the Pharmaceutical Industry, 2001, pp 349-374 from Springer

Abstract: Abstract The opinions and assertions expressed in this chapter are the private views of the authors. No endorsement by the Food and Drug Administration or the University of North Carolina at Chapel Hill is intended or should be inferred.

Keywords: Permutation Test; Sample Space; Adaptive Test; Rejection Region; Extreme Region (search for similar items in EconPapers)
Date: 2001
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-1-4757-3466-9_14

Ordering information: This item can be ordered from
http://www.springer.com/9781475734669

DOI: 10.1007/978-1-4757-3466-9_14

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().